Counselors in Mount Vernon, IA Accepting Medicare

7 Counselors found. Showing 1 - 7

Kelsey J Halemeyer, LMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 417 1st Ave Se, Mount Vernon, IA 52314 Phone: 319-573-8249

Madeline Burnham Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 104 2nd Ave Nw, Mount Vernon, IA 52314 Phone: 563-296-6225

Miriam Mcconnell Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: Ebersole Center, 600 First Street Sw, Mount Vernon, IA 52314 Phone: 319-895-4292

Christopher M Reid, TLMFT Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 306 Highway 1 S Ste B, Mount Vernon, IA 52314 Phone: 319-214-9009

Mrs. Tiffany L. Zarifkar, LMHC Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 104 2nd Ave Nw, Mount Vernon, IA 52314 Phone: 319-693-2266

Ben Mineck Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 204 Glenn St Se Ste 2, Mount Vernon, IA 52314 Phone: 319-423-2244

Katelyn Elizabeth Folkmann, T-LMHC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 104 2nd Ave Nw, Mount Vernon, IA 52314 Phone: 319-693-2266

News Archive

Renovis announces investigational medicine for multiple sclerosis study

Renovis announced today the initiation of a Phase Ia clinical trial for REN-850, an investigational oral small molecule that is being targeted for the treatment of multiple sclerosis (MS).

Genetic test predicts risk for Autism

A team of Australian researchers, led by University of Melbourne has developed a genetic test that is able to predict the risk of developing Autism Spectrum Disorder, ASD.

IQL conference explores development of ACO model

The American Medical Group Association is convening nearly 600 participants, representing the leaders of the nation's preeminent healthcare provider organizations, at IQL 2011: Creating High-Performing Care Organizations, September 19 - 21 at the Encore at Wynn Las Vegas.

Osiris Therapeutics resumes enrollment in Prochymal trial for treatment-resistant Crohn's disease

Osiris Therapeutics, Inc. today announced that it is resuming enrollment in its clinical trial evaluating Prochymal for patients with treatment-resistant Crohn's disease. The findings of an interim analysis showed that for the primary endpoint of disease remission, Prochymal is approaching statistical significance in the intent to treat (ITT) population, and has reached significance in the per protocol population.

Read more Medical News

› Verified 5 days ago